Nucleai's AI tech aids lung cancer study in Nature Communications, focused on NSCLC immunotherapy response.

Nucleai, an Israeli company specializing in AI-powered multimodal spatial biology, has revealed its involvement in a joint international research project featured in Nature Communications. The study, conducted by academic experts from The University of Queensland and Yale School of Medicine, delves into the correlation between the spatial arrangement and metabolic attributes of tumor cells and their reaction to immunotherapy in non-small cell lung cancer (NSCLC). Published results shed light on the significance of these factors in treatment response.